Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

07-23 -

More about the company

Quotes

Date	Price	Change	Volume
26-07-20	SEK 1.080	-1.82%	266,378
26-07-17	SEK 1.100	+0.92%	92,701
26-07-16	SEK 1.090	+0.37%	218,106
26-07-15	SEK 1.086	-1.09%	171,277
26-07-14	SEK 1.098	-3.17%	238,307

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-20 EDT			5-day change	1st Jan Change
1.080 ^SEK	-1.82%		-4.93%	-90.41%

06-25	Diamyd Medical Appoints New CFO	MT
06-25	Diamyd Medical names Mathias Skalmstad as new CFO	FW

Market Cap	167M 17.28M 15.15M 14M 12.87M 24.35M 1.67B 24.72M 65.54M 816M 65M 63.58M 2.83B	P/E 2026 *	-0.5x	P/E 2027 *	-1.71x
Enterprise Value	14.38M 1.49M 1.3M 1.2M 1.11M 2.09M 143M 2.12M 5.63M 70.09M 5.59M 5.46M 243M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	75.3%	Yield 2026 *	-	Yield 2027 *	-

06-25	Diamyd Medical Appoints New CFO	MT
06-25	Diamyd Medical names Mathias Skalmstad as new CFO	FW
06-25	Diamyd Medical AB Appoints Mathias Skalmstad as Chief Financial Officer, Effective July 1, 2026	CI
06-24	Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
06-24	Diamyd Medical CEO and major shareholder Anders Essen-Möller increases his stake	FW
06-24	Diamyd Medical reports wider Q3 loss	FW
06-23	Calendar Wednesday June 24	FW
06-23	Diamyd Medical Board to Focus on Strategic Review Following Close-out of Phase 3 Study	MT
06-23	Diamyd Medical signals it may broaden beyond health care after failed Phase 3 trial	FW
06-21	Diamyd Medical AB(OM:DMYD B) dropped from S&P Global BMI Index	CI
06-18	Calendar Monday June 22 - Friday June 26	FW
06-18	Diamyd Medical Reopens CFO Search After Interim Appointee Exits Role	MT
06-18	Diamyd seeks new interim CFO	FW

03-31	DNB Carnegie slashes Diamyd Medical valuation following trial failure	FW
03-30	DNB Carnegie awaits further clarity from Diamyd Medical - sharp negative share price reaction expected	FW
25-10-09	DNB Carnegie: Strong Finish for Diamyd Medical	FW
25-03-04	Penser temporarily removes fair value for Diamyd Medical due to the rights issue	FW
24-11-22	Penser reiterates fair value for Diamyd Medical after recruitment milestone	FW

Diamyd Medical AB Stock

Stocks

DMYD B

SE0005162880

Biotechnology & Medical Research

Valuation: Diamyd Medical AB

Chart: Diamyd Medical AB

Latest news : Diamyd Medical AB

Last Transcript: Diamyd Medical AB

Analysts' recommendations: Diamyd Medical AB

Press Releases: Diamyd Medical AB

Quotes and Performance

Course Extremes

Managers and Directors: Diamyd Medical AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-25	Mathias Skalmstad new CFO at Diamyd Medical	AQ
06-24	Diamyd Medical: A difficult reset, but not an empty hand – Q3 2025/26 review	AQ
06-24	Quarterly Report 3 25/26	AQ
06-23	Diamyd Medical provides update on Strategic Review	AQ
06-18	Diamyd Medical announces update regarding interim CFO	AQ

1 day	-1.82%
1 week	-4.93%
Current month	+5.88%
1 month	-0.74%
3 months	-22.30%
6 months	-91.12%
Current year	-90.41%

1 week	1.06	1.11
1 month	0.98	1.2
Current year	0.9	17.88
1 year	0.9	17.88
3 years	0.9	25
5 years	0.9	39.84
10 years	0.9	74.7

Manager	Title	Age	Since
Anders Essen-Möller CEO	Chief Executive Officer	85	2026-04-23
Anton Lindqvist CTO	Chief Tech/Sci/R&D Officer	46	2012-12-31
Martina Widman COO	Chief Operating Officer	45	-

Director	Title	Age	Since
Anders Essen-Möller CHM	Chairman	85	2023-10-01
Maria-Teresa Essen-Möller BRD	Director/Board Member	56	2008-12-31
Erik Kjellsson Nerpin CHM	Chairman	65	2026-04-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/27/25	Anders Essen-Möller	Don	Chief Executive Officer	100,000	0.0791%
5/5/25	Ulf Hannelius	Buy	Chief Executive Officer	1,000	0.0008%
5/2/25	Maja Johansson	Buy		1,020	0.0008%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAMYD MEDICAL AB	-1.82%	-4.93%	-88.87%	-89.22%	17.69M
ARGENX SE	+0.21%	-1.34%	+53.17%	+60.65%	53.83B
WUXI APPTEC CO., LTD.	+5.37%	+0.75%	+50.39%	+83.03%	52.1B
INSMED INCORPORATED	-1.20%	-7.43%	+4.35%	+406.96%	23.48B
BIONTECH SE	+0.74%	+0.73%	-16.23%	-15.55%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	+3.46%	+0.79%	+34.01%	-4.47%	19.36B
GENMAB A/S	-1.18%	-1.15%	+30.12%	-32.02%	17.56B
PHARMAESSENTIA CORPORATION	-1.67%	-8.56%	+163.95%	+284.69%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.62%	-2.42%	+29.70%	+663.64%	14.83B
EXELIXIS, INC.	-0.70%	-1.72%	+24.87%	+184.19%	14.06B
Average	+0.68%	-2.51%	+28.55%	+154.19%	23.36B
Weighted average by Cap.	+1.48%	-2.35%	+41.45%	+140.83%

	2026 *	2027 *
Net sales	-	-
Net income	-312M -32.22M -28.23M -26.1M -24M -45.38M -3.11B -46.08M -122M -1.52B -121M -119M -5.28B	-95M -9.81M -8.6M -7.95M -7.31M -13.82M -948M -14.03M -37.2M -463M -36.89M -36.09M -1.61B
Net Debt	-153M -15.8M -13.84M -12.8M -11.77M -22.26M -1.53B -22.59M -59.91M -746M -59.42M -58.12M -2.59B	-57M -5.89M -5.16M -4.77M -4.38M -8.29M -569M -8.42M -22.32M -278M -22.14M -21.65M -964M